Neurovance Announces Top-Line Study Results Suggest Lower Abuse Potential for Centanafadine Compared to Stimulants …

Neurovance, Inc. today announced top-line results from a human abuse liability study in recreational stimulant users. Centanafadine sustained-release is a novel triple reuptake inhibitor being developed for the treatment of adults with ADHD and has shown favorable efficacy with good tolerability in a phase 2a patient study.

from Content Keyword RSS


Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s